company background image
ACHL

Achilles TherapeuticsNasdaqGS:ACHL Stock Report

Last Price

US$3.83

Market Cap

US$155.5m

7D

-9.5%

1Y

n/a

Updated

27 Jan, 2022

Data

Company Financials +
ACHL fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

ACHL Stock Overview

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various types of solid tumors.

Price History & Performance

Summary of all time highs, changes and price drops for Achilles Therapeutics
Historical stock prices
Current Share PriceUS$3.83
52 Week HighUS$18.95
52 Week LowUS$3.55
Beta0
1 Month Change-27.74%
3 Month Change-38.72%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-76.86%

Recent News & Updates

Dec 27
Achilles Therapeutics (NASDAQ:ACHL) Is In A Good Position To Deliver On Growth Plans

Achilles Therapeutics (NASDAQ:ACHL) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Sep 09
Here's Why We're Not Too Worried About Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation

Here's Why We're Not Too Worried About Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

ACHLUS BiotechsUS Market
7D-9.5%-4.4%-5.1%
1Yn/a-21.2%3.3%

Return vs Industry: Insufficient data to determine how ACHL performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how ACHL performed against the US Market.

Price Volatility

Is ACHL's price volatile compared to industry and market?
ACHL volatility
ACHL Average Weekly Movement10.3%
Biotechs Industry Average Movement10.4%
Market Average Movement6.7%
10% most volatile stocks in US Market15.4%
10% least volatile stocks in US Market2.4%

Stable Share Price: ACHL is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: ACHL's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2016156Iraj Alihttps://www.achillestx.com

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various types of solid tumors. The company’s lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer.

Achilles Therapeutics Fundamentals Summary

How do Achilles Therapeutics's earnings and revenue compare to its market cap?
ACHL fundamental statistics
Market CapUS$155.51m
Earnings (TTM)-US$55.79m
Revenue (TTM)n/a

0.0x

P/S Ratio

-2.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ACHL income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
ExpensesUS$55.79m
Earnings-US$55.79m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-1.37
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did ACHL perform over the long term?

See historical performance and comparison

Valuation

Is Achilles Therapeutics undervalued compared to its fair value and its price relative to the market?

0.51x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ACHL's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ACHL's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ACHL is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: ACHL is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ACHL's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ACHL is good value based on its PB Ratio (0.5x) compared to the US Biotechs industry average (2x).


Future Growth

How is Achilles Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

-27.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ACHL is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ACHL is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ACHL is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ACHL is forecast to have no revenue next year.

High Growth Revenue: ACHL is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ACHL is forecast to be unprofitable in 3 years.


Past Performance

How has Achilles Therapeutics performed over the past 5 years?

-124.6%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: ACHL is currently unprofitable.

Growing Profit Margin: ACHL is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if ACHL's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare ACHL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ACHL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).


Return on Equity

High ROE: ACHL has a negative Return on Equity (-18.28%), as it is currently unprofitable.


Financial Health

How is Achilles Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: ACHL's short term assets ($298.3M) exceed its short term liabilities ($15.4M).

Long Term Liabilities: ACHL's short term assets ($298.3M) exceed its long term liabilities ($9.5M).


Debt to Equity History and Analysis

Debt Level: ACHL is debt free.

Reducing Debt: ACHL had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ACHL has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: ACHL has sufficient cash runway for 2.2 years if free cash flow continues to reduce at historical rates of 71.4% each year.


Dividend

What is Achilles Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ACHL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ACHL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ACHL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ACHL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ACHL's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.0yrs

Average management tenure


CEO

Iraj Ali (45 yo)

4yrs

Tenure

Dr. Iraj Ali, Ph.D. serves as Chief Executive Officer at Achilles Therapeutics Plc since December 10, 2018 and served as its Interim Chief Executive Officer since January 2018 until December 10, 2018. Dr....


Leadership Team

Experienced Management: ACHL's management team is seasoned and experienced (5 years average tenure).


Board Members

Experienced Board: ACHL's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: ACHL only recently listed within the past 12 months.


Top Shareholders

Company Information

Achilles Therapeutics plc's employee growth, exchange listings and data sources


Key Information

  • Name: Achilles Therapeutics plc
  • Ticker: ACHL
  • Exchange: NasdaqGS
  • Founded: 2016
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$155.511m
  • Shares outstanding: 40.60m
  • Website: https://www.achillestx.com

Number of Employees


Location

  • Achilles Therapeutics plc
  • 245 Hammersmith Road
  • London
  • Greater London
  • W6 8PW
  • United Kingdom

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/27 00:12
End of Day Share Price2022/01/26 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.